Development and Evaluation of Europium-Based Quantitative Lateral Flow Immunoassay for the Chronic Kidney Disease Marker Cystatin-C

J Fluoresc. 2022 Mar;32(2):419-426. doi: 10.1007/s10895-021-02886-y. Epub 2022 Jan 13.

Abstract

This study aimed to establish a Europium label time-resolved fluorescence immunoassay (TRFIA) to detect the chronic kidney disease (CKD) biomarker Cystatin-C. An Europium based Time resolved fluorescence immunoassay was developed to detect the concentration of Cystatin-C in a urine sample to increase the sensitivity with captured anti-Cystatin-C antibodies immobilized on nitrocellulose membrane and then bonded with detection anti-Cystatin-C labelled with CM-EU, followed by fluorescence measurement using time-resolved fluorometry in 15 min. The performance of this TRFIA was evaluated using the clinical urine serum and compared with the ELISA assays. The linear calibration range was 0.015-32 µg/ml, and the limit of detection (LOD) quantified was 0.0001 µg/ml. This current work has improved the LOD of our previous work from 0.013 µg/ml to 0.001 µg/ml. These results indicated that the CM-EU nanoparticle-based LFIA is rapid, more sensitive, reliable, and reproducible for point-of-care testing of Cys-C concentrations in urine.

Keywords: Europium nanoparticles; Fluorescent quantitative lateral flow assay; Sandwich assay; Time-resolved fluorescent.

Publication types

  • Evaluation Study

MeSH terms

  • Antibodies / urine
  • Biomarkers / urine
  • Cystatin C / immunology
  • Cystatin C / urine*
  • Europium*
  • Fluoroimmunoassay / methods*
  • Humans
  • Limit of Detection
  • Nanoparticles
  • Renal Insufficiency, Chronic / diagnosis*

Substances

  • Antibodies
  • Biomarkers
  • CST3 protein, human
  • Cystatin C
  • Europium